| 17 -0.058 (-0.34%) | 03-09 15:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.44 | 1-year : | 23.87 |
| Resists | First : | 17.5 | Second : | 20.44 |
| Pivot price | 16.98  |
|||
| Supports | First : | 16.16 | Second : | 15.34 |
| MAs | MA(5) : | 17.08 |
MA(20) : | 16.84 |
| MA(100) : | 16.63 |
MA(250) : | 14.94 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 61.5 |
D(3) : | 67.3 |
| RSI | RSI(14): 52.1 | |||
| 52-week | High : | 17.89 | Low : | 11.19 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SURI ] has closed below upper band by 48.9%. Bollinger Bands are 30.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.07 - 17.18 | 17.18 - 17.25 |
| Low: | 16.74 - 16.88 | 16.88 - 16.97 |
| Close: | 16.82 - 17.02 | 17.02 - 17.16 |
The Simplify Propel Opportunities ETF (SURI) seeks to provide long-term growth of capital by providing investors with exposure to biotech, pharma, health care technology, and life science companies that are believed to be overlooked by investors, thereby presenting significant opportunities for capital appreciation. The fund is sub-advised by Propel, which uses its deep scientific and commercial expertise in health sciences to identify the most promising health science investment opportunities.
Mon, 02 Mar 2026
Liquidity Mapping Around (SURI) Price Events - Stock Traders Daily
Sun, 08 Feb 2026
Understanding Momentum Shifts in (SURI) - Stock Traders Daily
Fri, 06 Feb 2026
ARTV Stock Price and Chart — NASDAQ:ARTV - TradingView
Tue, 25 Nov 2025
The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI - Yahoo Finance
Wed, 19 Mar 2025
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Wed, 12 Feb 2025
AARD Stock Price and Chart — NASDAQ:AARD - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|